NPs Basic Information

Name
Santonin
Molecular Formula C15H18O3
IUPAC Name*
(3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,4,5,9b-tetrahydro-3H-benzo[g][1]benzofuran-2,8-dione
SMILES
C[C@H]1[C@@H]2CC[C@]3(C=CC(=O)C(=C3[C@H]2OC1=O)C)C
InChI
InChI=1S/C15H18O3/c1-8-10-4-6-15(3)7-5-11(16)9(2)12(15)13(10)18-14(8)17/h5,7-8,10,13H,4,6H2,1-3H3/t8-,10-,13-,15-/m0/s1
InChIKey
XJHDMGJURBVLLE-BOCCBSBMSA-N
Synonyms
santonin; alpha-Santonin; 481-06-1; (-)-alpha-Santonin; Semenen; Santoninum; Santoninic anhydride; (-)-Santonine; (-)-Santonin; NSC4900; NSC-4900; 1VL8J38ERO; CHEBI:16363; .alpha.-Santonin; (3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,4,5,9b-tetrahydro-3H-benzo[g][1]benzofuran-2,8-dione; (3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,5,5a,9b-tetrahydronaphtho[1,2-b]furan-2,8(3H,4H)-dione; DSSTox_CID_25312; DSSTox_RID_80795; DSSTox_GSID_45312; NSC 4900; a-Santonin; l-.alpha.-Santonin; L-alpha-Santonin; (3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,4,5,9b-tetrahydro-3H-benzo[g]benzofuran-2,8-dione; Santonin [JAN]; naphtho[1,2-b]furan-2,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-, (3S,3aS,5aS,9bS)-; (-)-.alpha.-Santonin; Santonin [JAN:NF]; SR-01000635568; UNII-1VL8J38ERO; NCGC00016461-01; Santonin (TN); (3S,3AS,5AS,9BS)-3A,5,5A,9B-TETRAHYDRO-3,5A,9-TRIMETHYLNAPHTHO(1,2-B)FURAN-2,8(3H,4H)-DIONE; (3S,3aS,5aS,9bS)-3a,5,5a,9b-Tetrahydro-3,5a,9-trimethylnaphtho[1,2-b]furan-2,8(3H,4H)-dione; CAS-481-06-1; Naphtho(1,2-b)furan-2,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-, (3S,3aS,5aS,9bS)-; ()-alpha-Santonin; EINECS 207-560-7; MFCD00135865; NSC 41311; SANTONINE; Santonin (JP17); Spectrum_000790; SpecPlus_000318; AI3-19471; (-)- alpha -Santonin; Prestwick0_001070; Prestwick1_001070; Prestwick2_001070; Prestwick3_001070; Spectrum2_000699; Spectrum3_001245; Spectrum4_001476; Spectrum5_000151; SANTONINUM [HPUS]; SANTONIN [MART.]; SANTONIN [WHO-DD]; UPCMLD-DP084; (3S,5aS,9bS)-3a,5,5a,9b-Tetrahydro-3,5a,9-trimethylnaphtho[1,2-b]furan-2,8(3H,4H)dione; BSPBio_001060; BSPBio_002750; KBioGR_002051; KBioSS_001270; SPECTRUM300542; MLS002154141; DivK1c_006414; SPBio_000857; SPBio_002970; alpha-Santonin; (-)-Santonin; BPBio1_001166; CHEMBL259254; MEGxp0_001636; SCHEMBL1133565; .ALPHA.-SANTONIN [MI]; DTXSID7045312; UPCMLD-DP084:001; KBio1_001358; KBio2_001270; KBio2_003838; KBio2_006406; KBio3_002250; (-)-alpha-Santonin, >=99%; HMS1571E22; HMS2098E22; HMS2268H12; HY-B1761; ZINC3881689; Tox21_110445; CCG-40021; s3999; 11-Epiisoeusantona-1,4-dienic acid, 6alpha-hydroxy-3-oxo-, gamma-lactone; AKOS015895177; Tox21_110445_1; LMPR0103190001; SDCCGMLS-0066491.P001; (3S)-2,3,3a,4,5,5a,8,9bbeta-Octahydro-3,5abeta,9-trimethylnaphtho(1,2-b)furan-2,8-dion; Eudesma-1,4-dien-12-oic acid, 6-alpha-hydroxy-3-oxo-, gamma-lactone, (11S)-(-)-; Naphtho(1,2-b)puran-2,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-; (-)-alpha-Santonin, analytical standard; NCGC00161640-01; NCGC00161640-02; NCGC00161640-03; NCGC00263447-01; SMR000112520; AB00376930; CS-0013789; S0521; EN300-34530; C02206; D00154; WLN: T B566 COV LV IHTT&J E1 I1 M1; A827469; Q413166; SR-01000635568-1; SR-01000635568-4; SR-01000635568-5; BRD-K58787433-001-05-4; BRD-K58787433-001-08-8; BRD-K58787433-001-12-0; Santonin, European Pharmacopoeia (EP) Reference Standard; 11-Epiisoeusantona-1, 6.alpha.-hydroxy-3-oxo-, .gamma.-lactone; 3-(6-NITRO-2-OXO-1,3-BENZOXAZOL-3(2H)-YL)PROPANOICACID; Eudesma-1, 6.alpha.-hydroxy-3-oxo-, .gamma.-lactone, (11S)-; (11S)-6alpha-hydroxy-3-oxoeudesma-1,4-dien-12-oic acid gamma-lactone; 6alpha-hydroxy-3-oxo-11-epiisoeusantona-1,4-dienic acid gamma-lactone; Eudesma-1, 6.alpha.-hydroxy-3-oxo-, .gamma.-lactone, (11S)-(-)-; Naphtho[1,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-; 3a,5,5a,9b-Tetrahydro-3,5a,9-trimethyl-naphtho[1,2-b]puran-2,8(3H,4H)-dione; Eudesma-1,4-dien-12-oic acid, 6-alpha-hydroxy-3-oxo-, gamma-lactone, (11S)-; (3S,3AS,5AS)-3,5A,9-TRIMETHYL-3A,4,5,5A-TETRAHYDRONAPHTHO(1,2-B)FURAN-2,8(3H,9BH)-DIONE; (3S,3aS,5aS,9bS)-2,3,3a,4,5,5a,8,9b-Octahydro-3,5a,9-trimethylnaphtho(1,2-b)furan-2,8-dione; (3S,3aS,5aS,9bS)-3,5a,9-trimethyl-2H,3H,3aH,4H,5H,5aH,8H,9bH-naphtho[1,2-b]furan-2,8-dione; (3S,3aS,5aS,9bS)-3,5a,9-trimethyl-3a,4,5,5a-tetrahydronaphtho[1,2-b]furan-2,8(3H,9bH)-dione; 1,3,4,4a,7-Hexahydro-1-hydroxy-.alpha., 4a,8-trimethyl-7-oxo-2-naphthaleneacetic acid .gamma.-lactone; Naphtho[1,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-3,5a,9-trimethyl-, [3S-(3.alpha.,3a.alpha.,5a.beta.,9b.beta.)]-
CAS 481-06-1
PubChem CID 221071
ChEMBL ID CHEMBL259254
*Note: the IUPAC Name was collected from PubChem.
Chemical Classification:
  • Kingdom: Organic compounds
    • Superclass: Lipids and lipid-like mol
      • Class: Prenol lipids
        • Subclass: Terpene lactones
          • Direct Parent: Eudesmanolides, secoeudes

ClassyFire Version 1.0
PMID:27867422

NPs Species Source

Endophyte ID Endophyte Name Family Genus Taxonomy ID GenBank ID Closest GenBank ID Reference
Endophyte ID Endophyte Name Family Genus Taxonomy ID GenBank ID Closest GenBank ID Reference

NPs Content

*Note: The vaules in Content Percentage are calculated by dividing the content value by the maximum content value in NP Content.
**Note: The units with different NP content, due to their incomparable values, are separated into different tables.

NPs Biological Activity

Bioactivity Name Target ID Target Name Target Type Target Organism Target Organism ID Potency of Bioactivity Activity Type Value Unit Endophyte ID Endophyte Name
Bioactivity Name Target ID Target Name Target Type Target Organism Target Organism ID Potency of Bioactivity Activity Type Value Unit Endophyte ID Endophyte Name

NPs Physi-Chem Properties

Molecular Weight: 246.3 ALogp: 2.3
HBD: 0 HBA: 3
Rotatable Bonds: 0 Lipinski's rule of five: Accepted
Polar Surface Area: 43.4 Aromatic Rings: 3
Heavy Atoms: 18 QED Weighted: 0.616

NPs ADMET Properties*

ADMET: Absorption

Caco-2 Permeability: -4.613 MDCK Permeability: 0.00003200
Pgp-inhibitor: 0.067 Pgp-substrate: 0.002
Human Intestinal Absorption (HIA): 0.003 20% Bioavailability (F20%): 0.018
30% Bioavailability (F30%): 0.003

ADMET: Distribution

Blood-Brain-Barrier Penetration (BBB): 0.38 Plasma Protein Binding (PPB): 80.47%
Volume Distribution (VD): 1.406 Fu: 27.44%

ADMET: Metabolism

CYP1A2-inhibitor: 0.698 CYP1A2-substrate: 0.646
CYP2C19-inhibitor: 0.269 CYP2C19-substrate: 0.716
CYP2C9-inhibitor: 0.079 CYP2C9-substrate: 0.054
CYP2D6-inhibitor: 0.109 CYP2D6-substrate: 0.025
CYP3A4-inhibitor: 0.86 CYP3A4-substrate: 0.455

ADMET: Excretion

Clearance (CL): 11.434 Half-life (T1/2): 0.15

ADMET: Toxicity

hERG Blockers: 0.035 Human Hepatotoxicity (H-HT): 0.207
Drug-inuced Liver Injury (DILI): 0.15 AMES Toxicity: 0.161
Rat Oral Acute Toxicity: 0.916 Maximum Recommended Daily Dose: 0.882
Skin Sensitization: 0.297 Carcinogencity: 0.887
Eye Corrosion: 0.077 Eye Irritation: 0.132
Respiratory Toxicity: 0.975
*Note: the ADMET properties was calculated by ADMETlab 2.0. Reference: PMID: 33893803.

Similar Compounds*

Compounds similar to EMNPD with top10 similarity:

Similar NPs Similar Drugs
NPs ID NPs 2D Structure Similarity Score TTD ID Drug 2D Structure Similarity Score
ENC003248 0.315 D0K7LU 1.000
ENC003480 0.313 D0D2VS 0.279
ENC004782 0.307 D0C7JF 0.276
ENC002272 0.288 D0G6AB 0.261
ENC004596 0.276 D0A2AJ 0.253
ENC004595 0.276 D0S3WH 0.250
ENC004597 0.276 D0I5DS 0.245
ENC002338 0.271 D0G8BV 0.242
ENC002263 0.271 D0IL7L 0.237
ENC003409 0.266 D08PIQ 0.232
*Note: the compound similarity was calculated by RDKIT.